Table 3.
Patients with chronic heart failure who are pharmacologically treated and investigated according to the guidelines.
| N | Percentage (95% CI) | Differencea (95% CI) | P value | ||
|---|---|---|---|---|---|
| Number of patients | 2006 | 75 | |||
| 2008 | 94 | ||||
|
| |||||
| Investigation with ECO | 2006 | 42 | 56.0 (44.1, 67.5) | 10.0 (−6.0, 25.9) | 0.24 |
| 2008 | 62 | 66.0 (55.5, 75.4) | |||
|
| |||||
| Investigation with plasma NT-proBNP | 2006 | 32 | 42.7 (31.3, 54.6) | 46.7 (32.7, 60.7) | <10−4 |
| 2008 | 84 | 89.4 (81.3, 94.8) | |||
|
| |||||
| Treated with ACEI or ARB | 2006 | 45 | 60.0 (48.0, 71.1) | 11.3 (−4.30, 26.9) | 0.17 |
| 2008 | 67 | 71.3 (61.0, 80.1) | |||
|
| |||||
| ACEI recommended dose | 2006 | 16/45 | 35.6 (21.9, 51.2) | −1.3 (−20.4, 18.0) | 1 |
| 2008 | 23/67 | 34.3 (23.2, 46.9) | |||
|
| |||||
| Treated with beta-blocker | 2006 | 22 | 29.3 (19.4, 41.0) | 19.6 (4.0, 35.2) | 0.015 |
| 2008 | 46 | 48.9 (38.5, 59.5) | |||
aDifference between 2008 and 2006.